NCT07071727Recruiting
Short Course of Radiotherapy Prior to Surgery of Soft Tissue Sarcomas
Short Course Of Preoperative Radiotherapy in Head and Neck-, Trunk- and Extremity Soft Tissue Sarcomas; a Second Randomized Phase II Clinical Trial
Source: ClinicalTrials.gov · Last updated 19 Feb 2026
Brief summary (registry, in English)
Based upon the preliminary data derived from first SCOPES clinical trial and the results of patients treated during the recent COVID-19 pandemic, patients with soft tissue sarcomas (STS) can be preoperatively irradiated in a modestly hypofractionated schedule of 14 x 3 Gy. From a toxicity and efficacy point of view, this regimen equals the outcomes after a conventionally fractionated regimen of 25 x 2 Gy in five weeks. Moreover, the rationale for investigating (modest) hypofractionation in the clinic comes both from a logistic point of view (patient convenience and a lower pressure on radiotherapy equipment), form prior phase II clinical evidence and from (cellular) radiobiological observations. There is phase II trial evidence suggesting that even more (ultra-) hypofractionation to 5 x 6 Gy is also safe and effective. Within this study, patients will be randomized to receive either the modestly hypofractionated conventional schedule of 14 x 3 Gy or an even shorter preoperative regimen of 5 x 6 Gy, in the hypothesis that both the postoperative wound complication rate until 120 days after surgery, as well as the local control probability at two years are comparable in both arms.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- First submitted
- 8 Jul 2025
- Start date
- 11 Dec 2025
- Primary completion date
- 1 Nov 2028
- Lead sponsor
- The Netherlands Cancer Institute
- Diseases
- Sarcoma
- NCT number
- NCT07071727
What you commit to
- Study type: Interventional
- Planned participants: 150
- From 11 Dec 2025 to the primary completion date, 1 Nov 2028
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Myxoid liposarcomas, because they have shown to be exquisitely sensitive to a lower dose of radiation as compared to the 2 regimens tested in this trial.
- Intention to perform an isolated limb perfusion, instead of a tumor resection;
- Neoadjuvant chemotherapy both before and after radiotherapy.
Other illness
- Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial;
Age
- Prior malignancies; except another malignancy and disease-free for ≥ 5 years, or completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma;
Other
- Patients with locally recurrent sarcomas, regardless of the management of the first sarcoma diagnosis;
- Ewing sarcoma and other PNET family tumors, rhabdomyosarcomas (both pediatric and adult), osteosarcomas;
- Female patients who are pregnant;
Who the study is looking for
- Histologically confirmed intermediate to high grade soft tissue sarcoma localized to the head and neck area, to the trunk and chest wall or to the extremities, for which the standard treatment is a combination of and radiotherapy and surgery (deep seated and/or ≥ 5cm in largest tumor diameter and/or an anticipated close resection margin and/or grade II/III according to the FNCLCC definition);
- Absence of regional and/or distant disease. Patients must be staged by at least a CT scan of the chest. Staging may also be performed by FDG-PET scanning and/or total body MRI scans;
- WHO Performance Status ≤ 2;
- Able and willing to undergo preoperative radiotherapy;
- Able and willing to undergo definitive surgery;
- Able and willing to comply with regular follow-up visits;
- Able and willing to complete patient reported outcome questionnaires (health-related quality of life and cost effectiveness);
- Able and willing to undergo randomization;
- Age ≥ 18 years;
- Signed written informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Netherlands Cancer Institute Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Not yet recruiting |
| AUMC Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Recruiting |
| UMCG Coordinator of this site? Confirm its status | Groningen | Netherlands | Not yet recruiting |
| LUMC Coordinator of this site? Confirm its status | Leiden | Netherlands | Not yet recruiting |
| Maastro Coordinator of this site? Confirm its status | Maastricht | Netherlands | Recruiting |
| Radboudumc Coordinator of this site? Confirm its status | Nijmegen | Netherlands | Not yet recruiting |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.